Form 4: Ionis Pharma EVP Sells Shares Under 10b5-1 Plan

Joseph Baroldi, EVP and Chief Business Officer of Ionis Pharmaceuticals, sold 1,625 shares of common stock for $69.3693 per share on October 6, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Joseph Baroldi, EVP, Chief Business Officer of Ionis Pharmaceuticals Inc. (IONS), reported a sale of common stock.
• The transaction involved 1,625 shares of common stock.
• The shares were sold at a weighted average price of $69.3693 per share.
• The sale occurred on October 6, 2025.
• The transaction was executed pursuant to a Rule 10b5-1 Trading Plan adopted by Mr. Baroldi on May 2, 2025.
• Following the transaction, Mr. Baroldi directly beneficially owns 30,301 shares of common stock and indirectly owns 3,071 shares through his spouse.

Sentiment

Score: 6

Explanation: The sale of shares by an executive, even under a pre-arranged 10b5-1 plan, is generally viewed as neutral to slightly negative as it reduces insider ownership. However, the pre-planned nature mitigates concerns about opportunistic selling.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on immediate, non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the executive's direct equity stake in the company.

Risks

• While the sale was pre-planned, a reduction in insider ownership could be perceived by some investors as a slight decrease in management's direct alignment with shareholder interests, though this is mitigated by the 10b5-1 plan.

Future Outlook

N/A. This filing reports a past insider transaction and does not contain forward-looking statements or guidance.

Industry Context

N/A. This Form 4 filing reports an individual insider transaction and does not provide information related to broader industry trends or competitors.

Comparison to Industry Standards

• N/A. This filing reports a specific insider transaction and does not contain data suitable for comparison to global benchmarks or specific comparable companies/projects.

Corporate Governance

Related Party Transactions

• N/A. The filing notes indirect beneficial ownership by spouse, but no related party transactions are reported.

Stakeholder Impact

• Shareholders: May observe a slight reduction in direct insider ownership, though the 10b5-1 plan provides context.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific insider transaction.

Next Steps

• N/A. This filing reports a completed insider transaction and does not outline future actions, events, or milestones.

Key Dates

Recommendation

This Form 4 reports a routine insider sale executed under a pre-arranged 10b5-1 trading plan. Such sales are typically not indicative of a change in the company's fundamental outlook or a signal for immediate investment action. While it reduces the executive's direct stake, the planned nature suggests it's for personal financial management rather than a bearish view on the company. Therefore, a 'hold' recommendation is appropriate, as this filing alone does not provide sufficient new information to alter an existing investment thesis.

Keywords

Ionis Pharmaceuticals, IONS, Joseph Baroldi, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation, Biotechnology, Pharmaceuticals